| Metric | Q1 FY27 | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue from operations | 840.8 | 856.1 | 620.0 |
| Other income | 25.4 | 35.2 | 5.6 |
| Total income | 866.2 | 891.3 | 625.6 |
| Profit before exceptional items & tax | 206.6 | 200.0 | 76.6 |
| Profit before tax | 206.6 | 200.0 | 76.6 |
| Net profit | 159.4 | 149.0 | 58.2 |
| Operating margin | 23.9% | 22.4% | 12.2% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +173.90% |
|---|---|
| Net profit, quarter on quarter | +7.00% |
| Revenue, year on year | +35.60% |
| Operating profit, year on year | +155.20% |
| Operating profit, quarter on quarter | +10.00% |
BSE results filing, NSE: MARKSANS. Figures extracted from the filing.
Marksans Pharma Ltd: key numbers
- Share price
- ₹336.95
- Market cap
- ₹15,269 Cr
- Revenue (annual)
- ₹2,951 Cr
- Net profit (annual)
- ₹417.9 Cr
- P/E (TTM)
- 29.6×Sector 50.4×
- Promoter holding
- 43.87%+0.00% QoQ
- FII holding
- 17.47%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Marksans Pharma Ltd
All →Marksans Pharma Promoter Selling (Off-Market)
Director Sandra Saldanha gifted 2,28,273 shares of Marksans Pharma Ltd to her daughters in an off-market transaction. This internal transfer reallocates promoter-group equity holdings.
Marksans Pharma Other Announcement
Marksans Pharma intimated shareholders about SEBI's extended special window (Feb 2026–Feb 2027) for re-lodgement of pre-April-2019 physical share transfer deeds. No new business, capital, or operational event is disclosed.
Marksans Pharma Investor Presentation: Key Takeaways
Strong Q1FY27 performance driven by European growth and acquisitions. Marksans achieved highest-ever quarterly EBITDA and PAT, while crossing INR1,000 Cr cash balance.
- Call
- Guides 20% growth
Marksans Pharma Earnings Call Transcript: Key Takeaways
Marksans Pharma delivered record FY26 results, crossing INR 3,000 Cr net income with 20.4% EBITDA margins. Management strategy focuses on diversification across US, UK, and Europe markets with high cash generation.
- Call
- Guides 20% growth
Marksans Pharma Earnings Call: Key Takeaways
Marksans Pharma delivered record FY26 performance, crossing ₹3,000cr net income with highest-ever profitability. Strategy focuses on geographic diversification (US, UK, Australia) and transitioning to branded prescription generics.
Marksans Pharma Earnings Call: Key Takeaways
Marksans Pharma reported record Q3 FY26 revenue of ₹754cr (up 10.6% YoY) with EBITDA margins expanding to 21.3%. Strategy focuses on UK/US market expansion and new launches.